Decreased Access to Preventive Ophthalmology Screenings in a High Risk Indigent Population in Norfolk, VA
Methods: A survey of past vision care, co-morbidities, and family history of ophthalmologic disorders was administered to all patients of a student-run free clinic in Norfolk, VA (H.O.P.E.S) over a four-month period. A prospective analysis of survey data was performed.
Results: Ninety unique patients were seen over the data collection period, and 76 patients were included in analysis. 14 patients were excluded due to incomplete data. Of the surveyed sample, 25% had been diagnosed with diabetes, a substantially higher percentage than the 9.3% prevalence rate reported for the US as a whole. Of these surveyed diabetic patients, 52.6% were overdue for diabetic retinopathy screening, and 50.0% of the patients categorized as high glaucoma risk were overdue for glaucoma screening according to American Diabetes Association and American Glaucoma Society guidelines.
Conclusions: Low income, predominantly African American communities are at increased risk for preventable vision losses resulting from diabetic retinopathy and glaucoma. The population serviced by the H.O.P.E.S. free clinic is at severe risk for preventable vision losses.
Learning Areas:Assessment of individual and community needs for health education
Describe a key risk factors that place populations at risk for preventable blindness. Compare the prototypical high risk population to similar populations in the learner's area. Assess the need for diabetic retinopathy and glaucoma screening based on population characteristics
Keyword(s): Chronic Disease Prevention, Health Disparities/Inequities
Qualified on the content I am responsible for because: I am the founder of the EVMS HOPES Ophthalmology Specialty clinic, as well as Co-Director of the HOPES clinic itself. I have worked with the HOPES population throughout my medical education.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.